Skip to main content
    T

    Travere Therapeutics Inc (TVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $51.10
    +1.40 (+2.82%)

    Market Cap: $4.86B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Travere Therapeutics Inc (TVTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Travere Therapeutics (TVTX) has a market cap of $4.86B and an enterprise value of $5.35B. Revenue grew 49.38% over the last 12 months from the 12 months before. Its share count is down 7.79% from a year earlier.

    Total Valuation

    Enterprise value is 10.00% above the market cap, as debt exceeds cash.

    Market Cap$4.86B
    Enterprise Value$5.35B
    Latest price (Nov 17, 2026)$51.10

    Key Dates

    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.23% in the quarter ended Sep 30, 2026 and grew 10.30% a year over 2 years.

    Shares Outstanding94.63M
    Shares Change (YoY)-7.79%
    Shares Change (QoQ)+1.23%
    Share Count Growth (2Y CAGR)+10.30%

    Valuation Ratios

    Sales and book value multiples are 7.4x and 214.1x. Its year-end P/S ranged from 3.4x to 8.2x from 2016 to 2025.

    P/S Ratio7.4x
    Forward P/S6.4x
    P/B Ratio214.1x
    P/FCF Ratio53.0x
    P/OCF Ratio27.5x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 58.4x free cash flow.

    EV / Sales8.2x
    EV / FCF58.4x

    Price Statistics

    The stock is up 48.12% over 52 weeks and trades 7.63% below its 50-day average.

    Beta (1Y)1.26
    52-Week Change+48.12%
    1-Month Change+1.21%
    3-Month Change-22.53%
    6-Month Change+20.92%
    5-Year Change+74.90%
    10-Year Change+167.32%
    Total Return (1Y)+48.12%
    Total Return (3Y CAGR)+105.91%
    Total Return (5Y CAGR)+11.75%
    Return vs SPY (1Y)+30.39%
    Max Drawdown (1Y)-33.49%
    Max Drawdown (3Y)-46.44%
    Sharpe Ratio (1Y)0.60
    Correlation with SPY (1Y)0.29
    50-Day Average$55.32
    200-Day Average$47.87
    52-Week Range$22.59 to $68.73
    RSI (14 Days)46.6
    Average Volume (20 Days)2.20M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.00x current liabilities, and total debt is 27.00x shareholder equity.

    Current Ratio3.00x
    Quick Ratio2.95x
    Debt / Equity27.00x
    Debt / FCF6.69x
    Interest Coverage-17.01x

    Returns and Efficiency

    Return on invested capital is -23.06% over the last 12 months, against a 5-year average of -48.92%.

    Return on Equity (ROE)-538.02%
    Return on Assets (ROA)-14.32%
    Return on Invested Capital (ROIC)-23.06%
    Return on Capital Employed (ROCE)-23.67%
    ROA (5Y Average)-27.41%
    ROIC (5Y Average)-48.92%
    Asset Turnover0.94x
    Inventory Turnover3.74x
    Receivables Turnover6.92x
    Cash Conversion Cycle29 days

    Scores

    TVTX has an Altman Z-Score of 1.66, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score1.66
    Altman Z ZoneDistress
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $651.03M over the last 12 months.

    Revenue$651.03M
    Revenue Growth (YoY)+49.38%
    Gross Profit$616.67M
    Operating Income-$133.49M
    Pretax Income-$159.72M
    Net Income-$121.51M
    EBITDA-$98.07M
    EBIT-$150.85M
    Reported EPS (TTM)-$0.50

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 2.66% of the $848.23M in total assets.

    Cash and Equivalents$123.54M
    Total Debt$609.82M
    Net Debt$486.28M
    Net Debt Per Share$5.14
    Working Capital$422.53M
    Shareholder Equity$22.58M
    Book Value Per Share$0.24
    Tangible Book Value-$141.52M
    Total Assets$848.23M
    Total Liabilities$825.64M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $85.40M of capital spending, operating cash flow left $91.19M of free cash flow.

    Operating Cash Flow$176.59M
    Capital Expenditures$85.40M
    Free Cash Flow$91.19M
    FCF Per Share$0.95
    Depreciation and Amortization$52.78M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -20.50%.

    Gross Margin94.72%
    Operating Margin-20.50%
    Pretax Margin-24.53%
    Net Margin-18.66%
    EBITDA Margin-15.06%
    EBIT Margin-23.17%
    FCF Margin14.01%
    Gross Margin (5Y Average)95.95%

    Growth

    Revenue grew 64.89% a year over 3 years.

    Revenue Growth (3Y CAGR)+64.89%
    Revenue Growth (5Y CAGR)+19.87%
    Book Value Per Share Growth (2Y CAGR)-30.41%
    Tangible Book Per Share Growth (2Y CAGR)-87.73%

    Revenue and profit by year

    Dividends and Yields

    TVTX does not pay a dividend. Its free cash flow yield is 1.89%.

    FCF Yield1.89%
    Shareholder Yield0.00%

    Peer Position

    Against 8 similar companies, TVTX has the 7th highest P/S and the 5th highest ROIC.

    P/S Ratio7.4x vs 13.1x median
    ROIC-23.06% vs -31.02% median
    Revenue Growth (Trailing 4 Quarters, YoY)+49.38% vs +14.26% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 52.25% and EPS growth at 145.35% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+52.25%
    EPS Growth Forecast (2Y CAGR)+145.35%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TVTX

    What is TVTX's market cap?

    Travere Therapeutics has a market cap of $4.86B. Its enterprise value, which adds debt and subtracts cash, is $5.35B.

    How many shares of TVTX are outstanding?

    Travere Therapeutics has 94.63M shares outstanding. The count is down 7.79% from a year earlier.

    Does TVTX pay a dividend?

    No. Travere Therapeutics does not pay a dividend.

    How much debt does TVTX have?

    Travere Therapeutics has $609.82M of total debt and $123.54M of cash and equivalents, a net debt position of $486.28M.